Cargando…

A pancancer analysis of the oncogenic role of ZNRF2 in human tumours

Finding effective treatments for cancer requires a thorough understanding of how it develops and progresses. Recent research has revealed the crucial role that Zinc and ring finger 2 (ZNRF2) play in the progression of non‐small cell lung cancer (NSCLC) by controlling cell growth and death. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Fujie, Wu, Yunfei, Wang, Kai, Wang, Jiafan, Liu, Minghui, Sun, Xinlei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623518/
https://www.ncbi.nlm.nih.gov/pubmed/37551845
http://dx.doi.org/10.1111/jcmm.17900
_version_ 1785130755142189056
author Shi, Fujie
Wu, Yunfei
Wang, Kai
Wang, Jiafan
Liu, Minghui
Sun, Xinlei
author_facet Shi, Fujie
Wu, Yunfei
Wang, Kai
Wang, Jiafan
Liu, Minghui
Sun, Xinlei
author_sort Shi, Fujie
collection PubMed
description Finding effective treatments for cancer requires a thorough understanding of how it develops and progresses. Recent research has revealed the crucial role that Zinc and ring finger 2 (ZNRF2) play in the progression of non‐small cell lung cancer (NSCLC) by controlling cell growth and death. However, a comprehensive analysis of ZNRF2's role in cancer as a whole has yet to be conducted. Our study sought to investigate the impact of ZNRF2 on diverse human tumours, as well as the molecular pathways involved, using databases such as TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus) and the Human Protein Atlas (HPA), as well as several bioinformatic tools. Our findings indicate that ZNRF2 is generally expressed at higher levels in tumours than in normal tissues, and in some cancers, its levels correlate positively with disease stage, potentially predicting a poor prognosis for patients. We also discovered genetic changes in ZNRF2 among cancer patients, as well as its relationship with cancer‐related fibroblasts, endothelial cells and immune cell infiltration. Additionally, we explored potential molecular mechanisms of ZNRF2 in tumours, finding that it increases in hepatocellular carcinoma (HCC) tissues and that inhibiting its expression through ZNRF2 siRNA can limit HepG2 cell proliferation. Overall, our study provides a comprehensive overview of ZNRF2's oncogenic roles across various cancers.
format Online
Article
Text
id pubmed-10623518
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106235182023-11-04 A pancancer analysis of the oncogenic role of ZNRF2 in human tumours Shi, Fujie Wu, Yunfei Wang, Kai Wang, Jiafan Liu, Minghui Sun, Xinlei J Cell Mol Med Original Articles Finding effective treatments for cancer requires a thorough understanding of how it develops and progresses. Recent research has revealed the crucial role that Zinc and ring finger 2 (ZNRF2) play in the progression of non‐small cell lung cancer (NSCLC) by controlling cell growth and death. However, a comprehensive analysis of ZNRF2's role in cancer as a whole has yet to be conducted. Our study sought to investigate the impact of ZNRF2 on diverse human tumours, as well as the molecular pathways involved, using databases such as TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus) and the Human Protein Atlas (HPA), as well as several bioinformatic tools. Our findings indicate that ZNRF2 is generally expressed at higher levels in tumours than in normal tissues, and in some cancers, its levels correlate positively with disease stage, potentially predicting a poor prognosis for patients. We also discovered genetic changes in ZNRF2 among cancer patients, as well as its relationship with cancer‐related fibroblasts, endothelial cells and immune cell infiltration. Additionally, we explored potential molecular mechanisms of ZNRF2 in tumours, finding that it increases in hepatocellular carcinoma (HCC) tissues and that inhibiting its expression through ZNRF2 siRNA can limit HepG2 cell proliferation. Overall, our study provides a comprehensive overview of ZNRF2's oncogenic roles across various cancers. John Wiley and Sons Inc. 2023-08-08 /pmc/articles/PMC10623518/ /pubmed/37551845 http://dx.doi.org/10.1111/jcmm.17900 Text en © 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Shi, Fujie
Wu, Yunfei
Wang, Kai
Wang, Jiafan
Liu, Minghui
Sun, Xinlei
A pancancer analysis of the oncogenic role of ZNRF2 in human tumours
title A pancancer analysis of the oncogenic role of ZNRF2 in human tumours
title_full A pancancer analysis of the oncogenic role of ZNRF2 in human tumours
title_fullStr A pancancer analysis of the oncogenic role of ZNRF2 in human tumours
title_full_unstemmed A pancancer analysis of the oncogenic role of ZNRF2 in human tumours
title_short A pancancer analysis of the oncogenic role of ZNRF2 in human tumours
title_sort pancancer analysis of the oncogenic role of znrf2 in human tumours
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623518/
https://www.ncbi.nlm.nih.gov/pubmed/37551845
http://dx.doi.org/10.1111/jcmm.17900
work_keys_str_mv AT shifujie apancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT wuyunfei apancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT wangkai apancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT wangjiafan apancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT liuminghui apancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT sunxinlei apancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT shifujie pancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT wuyunfei pancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT wangkai pancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT wangjiafan pancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT liuminghui pancanceranalysisoftheoncogenicroleofznrf2inhumantumours
AT sunxinlei pancanceranalysisoftheoncogenicroleofznrf2inhumantumours